An eye drop designed to treat two pathways of dry eye disease significantly reduced a key sign of disease at 15 days.
The drop combines the active ingredients from two Bausch + Lomb dry eye drops: Xiidra (lifitegrast ophthalmic solution 5%) and Miebo (perfluorohexyloctane ophthalmic solution).
In a phase 2 study, patients using the combination drop had significantly lower total corneal fluorescein staining at day 15 than patients using lifitegrast only.
The drop will be studied further in a phase 3 trial, Bausch + Lomb announced during a research and development call.
The FDA approved Xiidra, an